Fig A3.
Disease-free survival (DFS) and overall survival (OS) comparing patients assigned to CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy with patients assigned to no CMF chemotherapy for triple-negative (A,D), human epidermal growth factor receptor 2–positive, endocrine-nonresponsive (B,E), and endocrine-responsive (C,F) subtypes. yr, year; Pts, patients.
